Replies to post #93 on Acorda Therapeutics Inc (ACORQ)

[surf1944]

6:11AM Acorda Therapeutics misses by $0.19, misses on revs; maintains AMPYRA rev guidance (ACOR) 27.16 : Reports Q1 (Mar) loss of $0.02 per share, $0.19 worse than the Thomson Reuters consensus of $0.17; revenues rose 246.3% year/year to $61.3 mln vs the $64.2 mln consensus. The co maintains its current year guidance of net revs of $205-$230 mln for AMPYRA. The co reaffirms its full year 2011 R&D expense guidance of $40-45 mln excluding share-based compensation charges.

[foodcourt1]

With todays news will probably hit $32 today.